Kin Seng Liem
YOU?
Author Swipe
View article: Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B
Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B Open
We studied whether 48 weeks of PEG‐IFN alfa‐2a add‐on increases HBsAg‐decline and clearance in HBeAg‐negative patients on long‐term nucleo(s)tide analogue (NA) therapy. In this investigator‐initiated, randomized, controlled trial conducted…
View article: Reply
Reply Open
View article: Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B
Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B Open
Background & Aims The use of complementary and alternative medicine (CAM) in patients with chronic hepatitis B (CHB) can interact with antiviral treatment or influence health‐seeking behaviour. We aimed to study the use of individual CAM m…
View article: Editorial: identifying candidates for pegylated interferon add‐on to entecavir therapy in patients with HBeAg‐positive chronic hepatitis B – authors' reply
Editorial: identifying candidates for pegylated interferon add‐on to entecavir therapy in patients with HBeAg‐positive chronic hepatitis B – authors' reply Open
Linked Content This article is linked to Liem et al and Peng papers. To view these articles, visit https://doi.org/10.1111/apt.15098 and https://doi.org/10.1111/apt.15136 .
View article: Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B
Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B Open
Summary Background Various treatment combinations of peginterferon (PEG‐IFN) and nucleos(t)ide analogues have been evaluated for chronic hepatitis B (CHB), but the optimal regimen remains unclear. Aims To study whether PEG‐IFN add‐on incre…
View article: Effect of Pegylated Interferon Add-On Therapy to Achieve Disease Remission in Patients with Chronic Hepatitis B
Effect of Pegylated Interferon Add-On Therapy to Achieve Disease Remission in Patients with Chronic Hepatitis B Open
Despite effective vaccination, chronic hepatitis B (CHB) poses a substantial hazard to public health with limited options for finite treatment. A pooled analysis was performed to investigate whether 24-48 weeks of peg-interferon (PEG-IFN) …
View article: Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review
Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review Open
In conclusion, evidence was found for prognostic value of FGFR1 expression in cancer-associated fibroblasts in HNSCC. Prognostic evidence on the other FGFR family members in HNSCC is limited and conflicting. This emphasizes the need for fu…